Oxaliplatin

Phase 2UNKNOWN

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Previously Treated Metastatic Non-Small Cell Lung Cancer

Conditions

Previously Treated Metastatic Non-Small Cell Lung Cancer

Trial Timeline

— → —

NCT ID

NCT00238849

About Oxaliplatin

Oxaliplatin is a phase 2 stage product being developed by Sanofi for Previously Treated Metastatic Non-Small Cell Lung Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT00238849. Target conditions include Previously Treated Metastatic Non-Small Cell Lung Cancer.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00238849	Phase 2	UNKNOWN	—	—	Previously Treated Metastatic Non-Small Cell Lung Cancer
NCT00846482	Pre-clinical	Completed	Feb 1, 2008	Dec 1, 2018	Colon Cancer
NCT00261092	Phase 2	Completed	Oct 1, 2005	—	Pancreatic Neoplasms
NCT00129870	Approved	Terminated	Feb 1, 2005	Dec 1, 2007	Colorectal Cancer
NCT00256308	Phase 2	Terminated	Feb 1, 2005	Oct 1, 2011	Head and Neck Cancer
NCT00263055	Approved	Completed	Aug 1, 2004	—	Colonic Neoplasms
NCT00280618	Phase 2	Completed	Jul 1, 2004	—	Carcinoma, Hepatocellular
NCT00263354	Phase 2	Completed	Oct 1, 2003	Jul 1, 2006	Stomach Neoplasms
NCT01042691	Phase 1	Completed	May 1, 2003	Nov 1, 2011	Unresectable Colorectal Liver Metastases
NCT00174564	Phase 2	Completed	Apr 1, 2003	Sep 1, 2006	Biliary Tract Neoplasms
NCT00259363	Phase 1/2	Terminated	Oct 1, 2002	—	Rectal Neoplasms
NCT00403624	Phase 1/2	Completed	Jul 1, 2001	Nov 1, 2005	Rectal Neoplasms

Competing Products

8 competing products in Previously Treated Metastatic Non-Small Cell Lung Cancer

See all competitors

Product	Company	Stage	Hype Score
SHR-A1811 + Pyrotinib in combination with Capecitabine. + SHR-A1811	Jiangsu Hengrui Medicine	Phase 3	77
AZD1775 + AZD1775 Placebo + Antimitotic Agent + pegfiligrastim	AstraZeneca	Phase 2	52
AZD1775 + AZD1775 Matching Placebo + pemetrexed + carboplatin	AstraZeneca	Phase 2	52
UFOX + Cetuximab + FOLFOX4 + Cetuximab	Merck	Phase 2	52
Idelalisib + Nab-paclitaxel + mFOLFOX6	Gilead Sciences	Phase 1	32
Bosutinib	Pfizer	Approved	84
CRS-207 + CRS-207 + nivolumab + GVAX + CY	Bristol Myers Squibb	Phase 2	51
Lenalidomide + Dexamethasone + Elotuzumab	Bristol Myers Squibb	Phase 3	76

Other Products from Sanofi

Adacel®Approved

LACTIC ACID(ND)Approved

DupilumabApproved

glatiramer acetateApproved

INSULIN GLULISINE + INSULIN GLARGINEApproved